

## Confirmed Speakers

### Confirmed Speakers

#### L01 - GPCR-ligand Structures through the Looking Glass: Computer-Aided Prediction of GPCR-Ligand Interactions



Dr Chris DE GRAAF  
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

#### L03 - Dual A2A-NR2B Antagonists: Potential for Unprecedented Activity in Parkinson's Disease



Mr Joël MERCIER  
(UCB, BRAINE-L'ALLEUD, Belgium)

#### L05 - Developing Ligands to Validate the Role of Receptors for Long-chain Fatty Acids in the Treatment of Type II Diabetes



Prof. Graeme MILLIGAN  
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

#### L06 - Positive Allosteric Modulators of mGlu2 Receptors for the Treatment of CNS Disorders



Dr Daniel OEHLRICH  
(JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium)

#### L04 - Biased Ligands, Allosteric Modulation: New Technological Approaches



Dr Stephan SCHANN  
(DOMAIN THERAPEUTICS, Strasbourg, France)

#### L02 - Nanobodies to Study GPCR Transmembrane Signaling: From Structures to Function to Drugs



Prof. Jan STEYAERT  
(VUB, Brussels, Belgium)

### Oral Communications

#### OC03 - Identification of Modulators for SUCNR1 BY Screening of a SOSA Library with a Bioluminescent cAMP Assay

Mrs Julie GILISSEN  
(ULG, Liege, Belgium)

#### OC01 - Discovery of Donecopride: Design of Dual 5-HT4R Agonists/AChE Inhibitors Multi-Target Directed Ligands for Alzheimer's Disease Treatment



Prof. Christophe ROCHAIS  
(UNIVERSITY OF CAEN, Caen, France)

#### OC02 - Novel Histamine H1-Receptor Fluorescent Antagonists for the Study of Receptor-Ligand Interactions

## Confirmed Speakers

---



Dr Leigh STODDART  
(UNIVERSITY OF NOTTINGHAM , Nottingham, United Kingdom)